Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005933-34
    Sponsor's Protocol Code Number:SFHI01
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-04-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2020-005933-34
    A.3Full title of the trial
    Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy
    Evaluatie van een gemodificeerde antibloedplaatjes therapie geassocieerd met een lage dosis rapamycine DESFirehawk bij patiënten met een acuut myocardinfarct die worden behandeld volgens een volledige revascularisatiestrategie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisation
    Een studie die is ontworpen om een gemodificeerde anti-bloedplaatjestherapie (geneesmiddelen die voorkomen dat bloedplaatjes stollen) te evalueren na implantatie van een Firehawk-medicijn-afgevende stent (metalen buis, die is bedekt met een medicijn en in verkalkte bloedvaten van het hart wordt ingebracht om ze open te houden) bij patiënten die een hartaanval hebben gehad en werden behandeld met volledige dottterbehandeling.
    A.3.2Name or abbreviated title of the trial where available
    TARGET FIRST
    TARGET FIRST
    A.4.1Sponsor's protocol code numberSFHI01
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSorin CRM SAS (Microport CRM)
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSorin CRM SAS (Microport CRM)
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSorin CRM SAS (Microport CRM)
    B.5.2Functional name of contact pointClinical Affairs
    B.5.3 Address:
    B.5.3.1Street Address4 Avenue Reaumur
    B.5.3.2Town/ cityClamart
    B.5.3.3Post code92140
    B.5.3.4CountryFrance
    B.5.4Telephone number+330146013409
    B.5.5Fax number+330146013333
    B.5.6E-mailyann.poezevara@crm.microport.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTICAGRELOR
    D.3.9.1CAS number 274693-27-5
    D.3.9.2Current sponsor codeTICAGRELOR
    D.3.9.3Other descriptive nameTICAGRELOR
    D.3.9.4EV Substance CodeSUB30898
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNACETYLSALICYLIC ACID
    D.3.9.1CAS number 50-78-2
    D.3.9.2Current sponsor codeACETYLSALICYLIC ACID
    D.3.9.3Other descriptive nameASPIRIN
    D.3.9.4EV Substance CodeSUB12730MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPRASUGREL
    D.3.9.1CAS number 150322-43-3
    D.3.9.2Current sponsor codePRASUGREL
    D.3.9.3Other descriptive namePRASUGREL
    D.3.9.4EV Substance CodeSUB30236
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with clinically stable, low to moderate complexity acute Myocardial Infarction (MI; troponine-positive Non-ST-Elevation MI or ST-Elevation MI) requiring primary Percutaneous Coronary Intervention. Subjects will be enrolled after having undergone successful complete revascularization with the study stent (Firehawk). Shortened DAPT of 1 month followed by 11 months P2Y12-Inhibitor only is compared to the current guideline-recommended 12-months DAPT.
    Klinisch stabiele patienten, die een laag tot matig complex acuut myocardinfarct (MI; troponine positieve niet-ST-Elevation MI of ST-Elevation MI) hebben doorgemaakt, waarvoor primaire percutane coronaire interventie nodig is. Proefpersonen worden ingesloten na een succesvolle volledige revascularisatie met de studie stent (Firehawk). Verkorte DAPT van 1 maand gevolgd door 11 maanden alleen P2Y12-Inhibitor wordt vergeleken met de door de huidige richtlijn-aanbevolen 12 maanden DAPT.
    E.1.1.1Medical condition in easily understood language
    Patients in the setting of heart attack related to a narrowing in one or more coronary artery who have received an invasive procedure to treat these narrowing(s) with (a) coronary stent(s).
    Patiënten na een hartaanval veroorzaakt door een vernauwing in een of meer kransslagaders die een dotter procedure hebben ondergaan om deze vernauwing(en) te behandelen met coronaire stent(s).
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10007541
    E.1.2Term Cardiac disorders
    E.1.2System Organ Class 10007541 - Cardiac disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to evaluate a modified Anti-Platelet Therapy, associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy, in reaching non-inferior NACE (among clinically stable, low to moderate complexity acute MI patients).

    Het primaire doel is om een gemodificeerde anti-trombocytentherapie te evalueren, geassocieerd met lage dosis rapamycine DES Firehawk bij acute myocard infarct patiënten behandeld met een volledige revascularisatie strategie, bij het bereiken van niet-inferieure NACE (onder klinisch stabiele, lage tot matig complexe acute MI-patiënten).
    E.2.2Secondary objectives of the trial
    The secondary objective is to evaluate a modified Anti-Platelet Therapy, associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction patients treated with complete revascularization strategy, in reducing bleeding events (among clinically stable, low to moderate complexity acute MI patients).

    Het secundaire doel is om een gemodificeerde anti-trombocytentherapie te evalueren, geassocieerd met lage dosis rapamycine DES Firehawk, bij acute myocardiale infarctpatiënten behandeld met een volledige revascularisatiestrategie, bij het verminderen van bloedingen (bij klinisch stabiele, lage tot matig complexe acute MI-patiënten).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all of the following criteria to be eligible for enrolment:
    Clinical
    • Subject is ≥ 18 years old
    •Subject has been hospitalised for troponin-positive Non-ST-Elevation MI, requiring early invasive treatment (PCI), or ST-Elevation MI requiring primary PCI, and this PCI occurred within the last 7 days
    •Subject is eligible for per-protocol antiplatelet treatments
    •Subject understands and agrees with the trial requirements and procedures, and provides written informed consent before any trial-specific tests or procedures are performed
    •Subject is willing to comply with all protocol requirements including antiplatelet treatment strategies and follow-up visits

    Procedural/angiographic (related to the treatment of the (N)STEMI
    •Successful revascularization:
    -Successful delivery and deployment of the Firehawk stent(s), with final residual stenosis of <30% (visually) for all target lesions
    -No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication/bleeding).
    •All the treated lesions:
    -In native coronary arteries only,
    -In vessels with visual reference diameter ≥2.25 mm and ≤ 4.00 mm
    -Implanted with the medical device
    -Maximum 3 lesions treated (*)
    -Maximum total stent length ≤ 80 mm.
    •Complete revascularization (**) performed when more than 1 significant lesion, during the index procedure or in staged procedure(s) occurring within 7 days from the index procedure. Physiologic assessment highly recommended for lesions with stenosis between 50% and 69%.
    (*) in 1 to 3 vessels.
    (**) Complete revascularization performed according to site routine practice and according to the European Society of Cardiology (ESC) guidelines.
    De proefpersonen dienen aan al de volgende criteria te voldoen om in aanmerking te komen voor insluiting in de studie:
    Klinisch
    • proefpersoon is ≥ 18 jaar oud.
    • De proefpersoon is opgenomen in het ziekenhuis voor troponine-positieve Non-ST-Elevatie-MI, waarvoor een vroege invasieve behandeling (PCI) vereist was, of voor ST-Elevatie-MI waarvoor een primaire PCI vereist was, en deze PCI werd binnen de laatste 7 dagen uitgevoerd.
    • De proefpersoon komt in aanmerking voor antiplaatjesbehandelingen volgens het protocol.
    • De proefpersoon begrijpt en gaat akkoord met de studievereisten en procedures, en ondertekent een schriftelijke toestemmingsverklaring voordat er studiespecifieke tests of procedures worden uitgevoerd.
    • De proefpersoon is bereid alle protocolvereisten na te leven waaronder de strategieën met antiplaatjesbehandeling en vervolgbezoeken.
    Procedureel/angiografisch (gerelateerd aan de behandeling van de (N)STEMI
    • Succesvolle revascularisatie:
    - Succesvolle ontplooiing en plaatsing van de Firehawk-stent(s), met uiteindelijke restenose van <30% (visueel) voor alle doellaesies
    - Geen optredenvan significante gebeurtenissen (zoals MI, niet-geplande revascularisatie, stenttrombose, beroerte, grote vasculaire complicatie/bloeding).
    • Alle behandelde laesies:
    - Enkel in native kransslagaders,
    - In bloedvaten met zichtbare referentiediameter ≥2,25 mm en ≤ 4,00 mm
    - geïmplanteerd met het medisch hulpmiddel
    - Maximaal 3 laesies behandeld (*)
    - Maximale totale stentlengte ≤ 80 mm.
    • Volledige revascularisatie (**) uitgevoerd indien meer dan 1 significante laesie, tijdens de indexprocedure of in gefaseerde procedure(s) binnen de 7 dagen na de indexprocedure. Fysiologische beoordeling wordt sterk aanbevolen voor laesies met stenose tussen 50% en 69%.
    (*) in 1 tot 3 bloedvaten.
    (**) Volledige revascularisatie uitgevoerd volgens de gangbare praktijk in de instelling en volgens de richtlijnen van de Europese Cardiologische Vereniging (ESC).
    E.4Principal exclusion criteria
    Patients fulfilling any of the following criteria are not eligible:
    •Subjects with prior STEMI or prior PCI within 12 months before index admission
    •Prior Coronary Artery Bypass Graft (CABG) Surgery
    •Cardiogenic shock
    •Secondary PCI
    •Fibrinolysis
    •Prior stent thrombosis
    •Planned PCI, CABG, or surgery within 12 months after the enrolment
    •Need for Oral Anti-Coagulation medications (or NOAC)
    •Ischemic stroke or intracerebral hemorrhage (spontaneous or traumatic) within 12 months prior to index procedure
    •eGFR <30 mL/min/1.73 m2 or dialysis
    •Active bleeding at time of inclusion or high risk for major bleeding
    •History of bleeding diathesis or coagulopathy or subject refuse blood transfusions
    •Stage B or C liver cirrhosis or active cancer within 12 months prior to index procedure (or currently receiving chemotherapy or planned to receive chemotherapy)
    •Baseline haemoglobin <13 g/dL (12g/dL for women) or anaemia requiring transfusion in the 4 weeks prior to index procedure
    •Moderate or severe thrombocytopenia (<100,000/µL)
    •Expected non-adherence to study protocol (such as current problems with substance abuse, severe impairment of cognitive skills, …)
    •Estimated life expectancy ≤12 months
    •Known hypersensitivity or contraindication to any medication used in the study or any of the study stent’s components/compounds (e.g., cobalt chromium alloy, rapamycin, or structurally related compounds, polymer or individual components, P2Y12 inhibitors, or aspirin).
    •Subject participates in another interventional (device or drug) clinical trial within 12 months after the index procedure
    •Subject is a woman who is pregnant, nursing or with known intention to procreate within 12 months after the index procedure (woman of child-bearing potential who is sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)). Investigator may require a pregnancy test to be performed within 7 days prior to the enrolment in women of child-bearing potential)

    Angiographic:
    •Any of :
    -In-stent restenosis or thrombosis
    -Chronic total occlusion
    -Severe calcification
    -True bifurcation disease (Medina class x,x,1) and side branch diameter ≥ 2mm (visual reference visual diameter) or bifurcation treated with 2 stents
    -Left main coronary artery lesion
    -Residual untreated dissection ≥ C
    -Implantation of a non-study stent
    •Extent and severity of disease is such that patient is deemed to receive preferentially CABG within 1 year (based on current ESC guidelines)
    Patiënten die voldoen aan een van de volgende criteria komen niet in aanmerking:
    • Proefpersonen met eerdere STEMI of eerdere PCI binnen de 12 maanden vóór de indexopname
    • Eerdere bypassoperatie (CABG)
    • Cardiogene shock
    • Secundaire PCI
    • Fibrinolyse
    • Eerdere stenttrombose
    • Geplande PCI, CABG of chirurgie binnen de 12 maanden na de aanmelding
    • Noodzaak voor orale antistollingsgeneesmiddelen (of NOAC)
    • Ischemische beroerte of intracerebrale bloeding (spontaan of traumatisch) binnen de 12 maanden voorafgaand aan de indexprocedure.
    • eGFR <30 mL/min/1,73 m2 of dialyse
    • Actieve bloeding op het moment van inclusie of hoog risico van grote bloeding
    • Voorgeschiedenis van bloedingsdiathese of coagulopathie of weigering van bloedtransfusies door proefpersoon
    • Fase B of C levercirrose of actieve kanker binnen de 12 maanden voorafgaand aan de indexprocedure (of krijgt momenteel chemotherapie of is gepland om chemotherapie te krijgen)
    • Baseline hemoglobine <13 g/dL (12g/dL voor vrouwen) of anemie waarvoor transfusie vereist is in de 4 weken voorafgaand aan de indexprocedure
    • Matige tot ernstige trombocytopenie (<100 000/L)
    • Verwachting dat het studieprotocol niet wordt nageleefd (zoals bekende problemen met misbruik van verslavende middelen, ernstige beperking van cognitieve vaardigheden enz.)
    • Geschatte levensverwachting ≤12 maanden
    • Bekende overgevoeligheid of contra-indicatie voor een geneesmiddel dat wordt gebruikt in de studie of voor een van de bestanddelen/stoffen in de stent (bijv. kobalt-chroomlegering, sirolimus of structuurgerelateerde stoffen, polymeer of individuele bestanddelen, P2Y12-remmers of aspirine).
    • De proefpersoon neemt al deel aan een andere interventionele klinische studie (van een hulpmiddel of geneesmiddel) binnen de 12 maanden na de indexprocedure.
    • De proefpersoon is een vrouw die zwanger is, borstvoeding geeft of met gekende intentie om zwanger te raken binnen de 12 maanden na de indexprocedure (een vrouw op vruchtbare leeftijd die seksueel actief is dient akkoord te gaan om een betrouwbaar anticonceptiemiddel te gebruiken vanaf het moment van de screening gedurende de 12 maanden na de indexprocedure). De onderzoeker kan eisen dat een zwangerschapstest bij vrouwen op vruchtbare leeftijd wordt uitgevoerd binnen de 7 dagen voorafgaand aan de aanmelding.
    Angiografisch:
    • Elke van de onderstaande:
    - In-stent-restenose of trombose
    - Chronische totale occlusie
    - Ernstige verkalking
    - Werkelijke bifurcatie (Medina-klasse x,x,1) en zijtakdiameter ≥ 2mm (visuele referentiediameter) of bifurcatie behandeld met 2 stents
    - Laesie linker hoofdstam kransslagader
    - Residuele onbehandelde dissectie ≥ C
    - Plaatsing van een andere dan de studiestent.
    • Omvang en ernst van de ziekte is zodanig dat verwacht wordt dat de patiënt binnen 1 jaar bij voorkeur een CABG zal ontvangen (op basis van de huidige ESC-richtlijnen)
    E.5 End points
    E.5.1Primary end point(s)
    Net Adverse Clinical and Cerebral Events (NACCE) defined as a composite of all cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 11 months post randomization (12 months post index procedure).
    Net Adverse Clinical en Cerebral Events (NACCE) gedefinieerd als een samenstelling van alle overlijden, niet-fataal myocardinfarct, definitieve/waarschijnlijke stenttrombose of Bleeding Academic Research Consortium (BARC) type 3 of 5 bloeding op 11 maanden na randomisering (12 maanden na de indexprocedure).
    E.5.1.1Timepoint(s) of evaluation of this end point
    11 months after randomization
    11 maanden na randomisatie
    E.5.2Secondary end point(s)
    The main secondary endpoint (powered) is BARC type 2, 3 or 5 bleeding events at 11 months post-randomization.

    Other secondary endpoints (exploratory) are clinical endpoints at 1 month, 6 months and 12 months:
    •All-cause death, non-fatal myocardial infarction, definite/probable stent thrombosis, or stroke
    •BARC 3 and 5 bleeding events
    •All-cause death or non-fatal myocardial infarction
    •Patient-oriented composite of major adverse cardiac and cerebral events (MACCE) including all-cause death, myocardial infarction, definite/probable stent thrombosis, any stroke, any Ischemia driven repeat revascularization,, or BARC bleeding events (type 2, 3, or 5)
    •Device oriented composite endpoint of Target Lesion Failure (cardiac death, target vessel related myocardial infarction, target lesion Ischemia Driven-revascularization)
    •MACE (cardiovascular death, myocardial infarction, Ischemia Driven-revascularization)
    •Definite or probable stent thrombosis
    •BARC 3 events
    •BARC 5 events
    •BARC 2 events
    •Cardiovascular death
    •Cardiac death
    •Non-cardiac death
    •Myocardial infarction
    •Cardiac death or non-fatal myocardial infarction
    •Cardiac death, myocardial infarction, or definite/probable stent thrombosis
    •Cardiovascular death, myocardial infarction, definite/probable stent thrombosis, or ischemic stroke
    •Ischemic stroke
    •Haemorrhagic stroke
    •Ischemia-driven target lesion revascularization
    •Ischemia-driven target vessel revascularization
    •Cardiovascular death, myocardial infarction, or ischemic stroke
    and each of the components of the primary and main secondary endpoints
    Het belangrijkste secondaire eindpunt (met power) is BARC type 2, 3 of 5 bloedingen op 11 maanden na randomisatie.

    Andere secundaire eindpunten (verkennend) zijn klinische eindpunten op 1 maand, 6 maanden en 12 maanden:
    • Alle Overlijden, niet-fataal myocardinfarct, definitieve/waarschijnlijke stenttrombose of beroerte
    • BARC 3 en 5 bloedingen
    • Alle Overlijden of niet-fataal myocardinfarct
    • Patiëntgerichte samenstelling van ernstig risico op cardiale en cerebrale incidenten (MACCE) waaronder overlijden door welke oorzaak dan ook, myocardinfarct, definitieve/waarschijnlijke stenttrombose, beroerte, herhaalde ischemie-gedreven revascularisatie of BARC bloedingen (type 2, 3 of 5)
    • Hulpmiddelgericht samengesteld eindpunt van target-laesiefalen (hartdood, myocardinfarct gerelateerd aan een target-bloedvat, ischemie-gedreven target-leasierevascularisatie)
    • MACE (cardiovasculaire dood, myocardinfarct, ischemie-gedreven revascularisatie)
    • Definitieve/waarschijnlijke stenttrombose of beroerte
    • BARC 3 bloedings voorvallen
    • BARC 5 bloedings voorvallen
    • BARC 2 bloedings voorvallen
    • Cardiovasculaire dood
    • Cardiale dood
    • Niet Cardiale dood
    • Myocardinfarct
    • Cardiale dood of niet-fataal myocardinfarct
    • Cardiale dood, myocardinfarct of definitieve/waarschijnlijke stenttrombose of beroerte
    • Cardiovasculaire dood, myocardinfarct, definitieve/waarschijnlijke stenttrombose of ischemische beroerte
    • Ischemische beroerte
    • Hersenbloeding
    • Ischemie-gedreven target-leasierevascularisatie
    • Ischemie-gedreven target-bloedvatrevascularisatie
    • Cardiovasculaire dood, myocardinfarct of ischemische beroerte
    en elk van de onderdelen van de primaire en secundaire hoofdeindpunten
    E.5.2.1Timepoint(s) of evaluation of this end point
    Main secondary endpoint 11 months post-randomization. Other secondary endpoints at 1 month, 6 months and 12 months.
    Belangrijkste secundair eindpunt 11 maanden na randomisatie. Andere secundaire eindpunten op 1 maand, 6 maanden en 12 maanden.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    1 maand DAPT gevolgd door monotherapie met een P2Y12 inhibitor
    1 month of DAPT followed by monotherapy with a P2Y12 inhibitor
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    12 maanden DAPT (volgens de huidige richtlijnen voor ACS patiënten)
    12 months of DAPT (as per current guidelines for ACS patients)
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA48
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Switzerland
    Austria
    Belgium
    France
    Italy
    Netherlands
    Portugal
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 800
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1446
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state240
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 2126
    F.4.2.2In the whole clinical trial 2246
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none: at the end of the trial, patients will be followed according to current care practice
    Geen: aan het einde van de studie zullen de patiënten de routine behandeling krijgen.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-04-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-04-13
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 11:41:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA